Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sarah Morice
Observed name:
S Morice
Institutions:
University of Zurich,
Universitätsklinik Balgrist
Observed institutions:
Centre National de la Recherche Scientifique,
Inserm,
University of Zurich,
Universitätsklinik Balgrist,
Université Bretagne Loire,
Université de Nantes,
Université Pierre-et-Marie-Curie,
Nantes Université
show all 8
ORCID:
0000-0002-5692-5980
Observed ORCID:
0000-0002-5692-5980
OpenAlex ID:
A5009632216
New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
2019
·
Geoffroy Danieau
, Sarah Morice
, et al.
·
International Journal of Molecular Sciences
·
93
PDF
The YAP/TEAD Axis as a New Therapeutic Target in Osteosarcoma: Effect of Verteporfin and CA3 on Primary Tumor Growth
2020
·
Sarah Morice
, Mathilde Mullard
, et al.
·
Cancers
·
52
PDF
Tissue-specific pattern of variant transcripts of the human gonadotropin-releasing hormone receptor gene
1999
·
ML Kottler
, F Bergametti
, et al.
·
European Journal of Endocrinology
·
46
Overexpression of the Ubiquitin Specific Proteases USP43, USP41, USP27x and USP6 in Osteosarcoma Cell Lines: Inhibition of Osteosarcoma Tumor Growth and Lung Metastasis Development by the USP Antagonist PR619
2021
·
Mélanie Lavaud
, Mathilde Mullard
, et al.
·
Cells
·
44
PDF
Connexin43 intercellular communication drives the early differentiation of human bone marrow stromal cells into osteoblasts
2017
·
Julie Talbot
, Régis Brion
, et al.
·
Journal of Cellular Physiology
·
41
PDF
Hippo/YAP Signaling Pathway: A Promising Therapeutic Target in Bone Paediatric Cancers?
2020
·
Sarah Morice
, Geoffroy Danieau
, et al.
·
Cancers
·
39
PDF
PAX3-FOXO1 uses its activation domain to recruit CBP/P300 and shape RNA Pol2 cluster distribution
2023
·
Yaw Asante
, Katharina Benischke
, et al.
·
Nature Communications
·
38
PDF
ICG-001, an Inhibitor of the β-Catenin and cAMP Response Element-Binding Protein Dependent Gene Transcription, Decreases Proliferation but Enhances Migration of Osteosarcoma Cells
2021
·
Geoffroy Danieau
, Sarah Morice
, et al.
·
Pharmaceuticals
·
27
PDF
SHH Signaling Pathway Drives Pediatric Bone Sarcoma Progression
2020
·
Frédéric Lézot
, Isabelle Corre
, et al.
·
Cells
·
24
PDF
Involvement of the TGF-β Signaling Pathway in the Development of YAP-Driven Osteosarcoma Lung Metastasis
2021
·
Sarah Morice
, Geoffroy Danieau
, et al.
·
Frontiers in Oncology
·
17
Sonic Hedgehog Signature in Pediatric Primary Bone Tumors: Effects of the GLI Antagonist GANT61 on Ewing’s Sarcoma Tumor Growth
2020
·
Mathilde Mullard
, Marie Cadé
, et al.
·
Cancers
·
17
PDF
Antagonistic Functions of Connexin 43 during the Development of Primary or Secondary Bone Tumors
2020
·
Julie Talbot
, Maryne Dupuy
, et al.
·
Biomolecules
·
16
PDF
HIF1α gates tendon response to overload and drives tendinopathy independently of vascular recruitment
2026
·
Greta Moschini
, Archana G. Mohanan
, et al.
·
Science Translational Medicine
·
13
Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer
2024
·
Sara G. Danielli
, Jakob Wurth
, et al.
·
Molecular Cancer Therapeutics
·
3
The hegemonic EWSR1::ETS oncoprotein overrules core regulatory circuitry principles in Ewing sarcoma
2025
·
Sandrine Grossetete
, Sakina Zaidi
, et al.
·
npj Precision Oncology
·
2
Figure S3 from Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer
2026
·
Sara G. Danielli
, Jakob Wurth
, et al.
Figure S1 from Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer
2026
·
Sara G. Danielli
, Jakob Wurth
, et al.
Figure S5 from Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer
2026
·
Sara G. Danielli
, Jakob Wurth
, et al.
Figure S4 from Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer
2026
·
Sara G. Danielli
, Jakob Wurth
, et al.
Figure S2 from Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer
2026
·
Sara G. Danielli
, Jakob Wurth
, et al.
Data from Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer
2024
·
Sara G. Danielli
, Jakob Wurth
, et al.
Figure S5 from Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer
2024
·
Sara G. Danielli
, Jakob Wurth
, et al.
Supplementary Data from Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer
2024
·
Sara G. Danielli
, Jakob Wurth
, et al.
Figure S1 from Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer
2024
·
Sara G. Danielli
, Jakob Wurth
, et al.
Figure S4 from Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer
2024
·
Sara G. Danielli
, Jakob Wurth
, et al.
Show more works
View as search
Works count:
42
Citation count:
472
H-index:
13
I10-index:
13
Year
Topic
Type